Lisata Therapeutics licenses certepetide to Kuva Labs for solid tumor imaging

LISATA THERAPEUTICS, INC.

Upfront cash license fee of $1.0M payable over 12 months in four installments.
Development milestones up to $1.5M; commercial milestones up to $17.5M; 5% royalty on net sales.
Kuva assumes full R&D and commercialization costs; Lisata to supply certepetide for clinical and commercial use.
Partnership combines Lisata's certepetide with Kuva's NanoMark imaging technology for solid tumors.
Agreement effective November 30, 2024; Kuva may terminate on 60-day notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.